Show simple item record

dc.contributor.authorWatts, G.
dc.contributor.authorNorman, Richard
dc.identifier.citationWatts, G. and Norman, R. 2018. Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’ [Editorial]. International Journal of Cardiology. 267: pp: 193-194.

Seminal data from population genetics have presaged the development of several novel lipid-regulating drugs and the prospect of more effectively addressing high residual risk of cardiovascular disease (CVD) in patients receiving secondary prevention therapies [1]. The most impressive development is the identification of proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of the intracellular cycling of the low-density lipoprotein (LDL) receptor, as a target for lowering LDL-cholesterol (LDL-C) [2]. This journey most recently entered the phase of large scale CV outcome trials [2]. The most widely tested method for inhibiting PCSK9 entails the use of humanized monoclonal antibodies (mAbs) [2]. However, their high acquisition costs and budgeting impact on healthcare are concerning [3].

In this issue, Kumar et al. report an economic evaluation of PCSK9 inhibitors in Australia [4]. The secondary prevention population relates to the FOURIER trial [5]. Relative to placebo, they estimated an incremental cost-effectiveness ratio (ICER), reporting the cost per quality-adjusted life year (QALY) being higher than $300,000 [4]. The authors concluded that a significant reduction in cost is required to reach the point at which PCSK9 inhibitors can be recommended as cost-effective, an appropriate conclusion. There are a number of considerations, both clinical and economic, pointing to future research for demonstrating cost-effectiveness in specific populations.

dc.publisherElsevier Ireland Ltd.
dc.titleSquaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
dc.typeJournal Article
dcterms.source.titleInternational Journal of Cardiology
curtin.departmentSchool of Public Health
curtin.accessStatusOpen access
curtin.contributor.orcidNorman, Richard [0000-0002-3112-3893]

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as